Matthew C. Hill - 13 Aug 2024 Form 4/A - Amendment Insider Report for Apyx Medical Corp (APYX)

Reporting relationship: Chief Financial Officer
Issuer ticker: APYX
Reported as of: 13 Aug 2024
Net transaction value: +$6,780
SEC form: 4/A - Amendment
Accepted by SEC: 03 Mar 2025, 16:05:12 UTC
Original report date: 13 Aug 2024
Prior SEC filing: 11 Jan 2024
Next SEC filing: 17 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew C. Hill

Key filing fact

Matthew C. Hill filed Form 4/A - Amendment for Apyx Medical Corp (APYX) on 03 Mar 2025.

Key facts

This page summarizes Matthew C. Hill's Form 4/A - Amendment filing for Apyx Medical Corp (APYX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Mar 2025, 16:05.

Change

Previous filing in this sequence was filed on 11 Jan 2024.
Current net transaction value: +$6,780.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APYX transaction

Common Stock

Purchase

Transaction value: $6,780
Shares: +6,000
Change %: +240%
Price: $1.13
Shares after: 8,500
Date: 13 Aug 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects the addition of 664 shares that were inadvertently omitted from the Reporting Person's original Form 4.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $1.12 to $1.13. The reported price in Column 4 is a weighted average price, rounded to the nearest hundredth. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.